On 28 February 2020, orphan designation EU/3/20/2255 was granted by the European Commission to Celgene Europe B.V., the Netherlands, for luspatercept (also known as ACE-536) for the treatment of myelofibrosis.
The sponsorship was transferred to Bristol-Myers Squibb Pharma EEIG, Ireland in February 2021.
|Disease / condition||
Treatment of myelofibrosis
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.